Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRevelation Biosciences Inc

Revelation Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.94 USD -0.17 ( 4.14%)
Last update at 2026-11-10T21:00:00Z
VOLUME
9482
Market Cap
3.82M
P/E
0.04

Momentum Score

…

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.58
Low
4.07
High
52 Week Price Range
0.88
Low
6.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
4.11
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
90.91M
Debt / Equity
0.08
ROE
-154.77%
Net Debt
-9.95M
ROCE
-94.64%
Diluted EPS TTM
27.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.91M -15.04M -0.12M -10.83M -11.99M
Net income -8.91M -15.04M -0.12M -10.79M -11.99M
Selling general administrative 5.01M 4.43M 4.51M 5.49M 5.04M
Selling and marketing expenses - - 0.03M - -
Gross profit -0.03M -0.03M -0.03M - -
Reconciled depreciation 0.03M 0.03M 0.03M 0.03M 0.02M
Ebit -9.07M -7.98M -8.66M -10.86M -11.95M
Ebitda -9.04M -7.95M -8.63M -10.84M -11.93M
Depreciation and amortization 0.03M 0.03M 0.03M 0.03M 0.02M
Operating income -9.07M -7.98M -8.66M -10.86M -11.95M
Other operating expenses 9.07M 7.98M 8.66M 10.86M 11.95M
Interest expense - - - 0.03M 0.04M
Income tax expense - - 0.00M -0.03M 0.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 9.07M 7.98M 8.66M 10.86M 11.95M
Cost of revenue 0.03M 0.03M 0.03M - -
Total other income expense net 0.16M -7.06M 8.54M 0.03M -0.04M
Net income from continuing ops -8.91M -15.04M 0.88M -10.83M -11.99M
Net income applicable to common shares - - - - -2.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.58M 6.62M 12.21M 5.50M 2.04M
Other current assets 0.11M 0.07M 0.08M 0.07M 0.64M
Total liab 2.72M 1.91M 5.56M 4.45M 2.14M
Total stockholder equity 8.86M 4.71M 6.65M 1.05M -0.10M
Other current liab 1.40M 1.13M 4.20M 3.90M 1.53M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 7.48M
Retained earnings -49.42M -40.51M -25.47M -25.35M -14.52M
Other liab - - - - 50.72M
Other assets - - - - 48.30M
Cash 10.70M 6.50M 11.99M 5.25M 1.27M
Total current liabilities 2.00M 1.91M 5.56M 4.45M 2.14M
Net debt -9.95M -6.50M -11.99M -5.25M -1.26M
Short term debt 0.02M - - - 0.02M
Short long term debt total 0.75M - - - 0.02M
Other stockholder equity 58.28M 45.21M 32.11M 26.40M 6.93M
Property plant equipment - - - - 0.13M
Total current assets 10.81M 6.57M 12.08M 5.41M 1.91M
Net tangible assets - - - - -7.82M
Short term investments - 6492.52M - - -
Accounts payable 0.58M 0.78M 1.36M 0.55M 0.60M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.03M 56.28M 0.07M - 48.17M
Non current assets total 0.77M 0.06M 0.14M 0.09M 0.13M
Capital lease obligations 0.75M 0.00M - 0.00M 0.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M 0.00M 0.00M -0.13M
Change to liabilities - - - - 2.29M
Total cashflows from investing activities - -0.02M - - 25.74M
Net borrowings - - 0.00M - 0.75M
Total cash from financing activities 12.47M 12.85M 14.03M 15.20M 8.00M
Change to operating activities - - - - 0.13M
Net income -8.91M -15.04M -0.12M -10.83M -11.99M
Change in cash 4.20M -5.49M 6.74M 3.98M -3.22M
Begin period cash flow 6.50M 11.99M 5.25M 1.27M 4.49M
End period cash flow 10.70M 6.50M 11.99M 5.25M 1.27M
Total cash from operating activities -8.27M -18.32M -7.29M -11.22M -11.09M
Issuance of capital stock 3.39M 5.42M 14.03M 11.72M 8.00M
Depreciation 0.03M 0.03M 0.03M 0.03M 0.02M
Other cashflows from investing activities - -19.15M 0.00M - 25.74M
Dividends paid 5951.53M - - - -
Sale purchase of stock - 0.00M -0.01M - -
Other cashflows from financing activities 18409.95M 7.43M -0.00M 6.78M 7.40M
Change to netincome - - - - -1.02M
Capital expenditures 0.00M 0.02M 0.00M 0.00M 0.13M
Change in working capital -0.01M -3.42M 0.98M -0.73M 0.36M
Stock based compensation 0.60M 0.17M 0.16M 0.30M 0.47M
Other non cash items 0.03M -0.06M -8.33M 0.01M 0.05M
Free cash flow -8.27M -18.34M -7.29M -11.22M -11.22M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
REVB
Revelation Biosciences Inc		 -0.17
4.14%		 3.94 0.04 0.89 2.88 0.36 -1.02
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Revelation Biosciences Inc

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

4660 La Jolla Village Drive, San Diego, CA, United States, 92122

650 800 3717

https://www.revbiosciences.com

8

Name Title Year Born
Mr. James M. Rolke CEO & Director 1969
Mr. Chester Stanley Zygmont III Chief Financial Officer 1980
Ms. Sandra Vedrick VP of HR & Investor Relations NA
Ms. Carol Odle Sr. Director of Clinical Projects NA
Mr. Chester Stanley Zygmont III CFO & Corporate Secretary 1980
Ms. Sandra Vedrick Vice President of Human Resources & Investor Relations NA
Ms. Carol Odle Senior Director of Clinical Projects NA
Mr. James M. Rolke Chairman & CEO 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…